Peer-reviewed veterinary case report
Comparing two desoxycortone pivalate treatments for dogs with low
By Farr, Hayley et al.·Published in The Veterinary record·2020·Dechra Development LLC, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Randomised clinical non-inferiority trial comparing two formulations of desoxycortone pivalate for the treatment of canine primary hypoadrenocorticism.
- Species:
- dog
Plain-English summary
A group of dogs with primary hypoadrenocorticism (a condition where the adrenal glands don't produce enough hormones) were treated with two different formulations of a medication called desoxycortone pivalate (DOCP). The dogs received either Zycortal, given under the skin, or Percorten-V, given in the muscle, and both treatments were found to be equally effective after 90 days. Most dogs showed improvement, with common symptoms being excessive thirst and urination. Both medications were safe to use alongside other hormone treatments, helping the dogs manage their condition well.
People also search for: dog adrenal gland disease treatment · primary hypoadrenocorticism in dogs · Zycortal vs Percorten-V for dogs
Abstract
BACKGROUND: This clinical trial compared two formulations of desoxycortone pivalate (DOCP) for treating the mineralocorticoid deficit in dogs with primary hypoadrenocorticism (PH). METHODS: At veterinary clinics in the USA and France, dogs with PH (n=152) were randomised (3:1) to receive approximately monthly treatments with either the test product, Zycortal (Dechra), administered subcutaneously (n=113), or the control product, Percorten-V (Novartis Animal Health), administered intramuscularly (n=39), both at an initial dose of 2.2 mg/kg DOCP. Treatment administrators were unblinded; veterinarians assessing clinical signs were blinded; owners were blinded until at least day 90, the primary end point. Veterinarians assessed treatment outcome based on all of the following: clinical signs; sodium concentrations; potassium concentrations. Dogs received concurrent glucocorticoid therapy throughout the trial. Non-inferiority was assessed using a generalised linear mixed model to compare success rates between groups. RESULTS: Success rates at day 90 were similar between groups (per-protocol population at day 90: Zycortal 87/101, 86.2 per cent, Percorten-V 29/34, 85.1 per cent). Zycortal was non-inferior to Percorten-V as the upper limit of the 95 per cent CI for the difference between groups was 13.6 per cent. Polydipsia and polyuria were the most common clinical observations. CONCLUSION: Both products, in combination with glucocorticoid therapy, were safe and effective in treating PH.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/31974265/